CLINUVEL PHARMACEUTICALS LTD, a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders, today announced its Appendix 4C – Quarterly Cashflow Report for the period 01 October to 31 December 2019. All figures are rounded and reported in Australian dollars.
Recent Posts
Statement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read More